Treatment of Patients After Lung Transplantation With Covid Infection During Long-Term Follow-Up
Transplantation Proceedings · 2024
DOI: 10.1016/j.transproceed.2024.03.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplantation Proceedings, 2024. Verfasst von Sławomir Żegleń und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pneumonology and Allergology, Medical University of Gdansk, Poland. Electronic address: slawomir.zeglen@gumed.edu.pl. Hauptthemen laut MEDLINE: Lung Transplantation, COVID-19, Antiviral Agents. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Patients undergoing lung transplantation are routinely managed with lifelong immunosuppression, which is associated with a heightened risk for infections. This study delves into the therapeutic challenges and strategies for managing lung transplant recipients (LTRs) infected with COVID-19 during long-term follow-up. METHODS: The was a case series analysis, among which nonstandard therapies consisting of targeted antibody treatment, antiviral drugs, or anti-interleukin-6 drugs were applied in patients after lung transplantation. Additional analysis of laboratory test results for systemic inflammation and imaging studies was also carried out. The study was limited to a dedicated COVID-19 center, commonly known as a temporary hospital, and included patients infected with COVID-19 in the late post-lung transplant period (home-related infection). RESULTS: Fifteen post-lung transplantation patients with current COVID-19 infection were treated with antibodies such as tocilizumab, casirivimab, imdevimab, and regdanvimab. Of these patients, 1 was given tocilizumab (7%), 8 casirivimab and imdevimab (53%), and 2 regdanvimab (13%). Of the 15 lung transplant recipients studied, 8 presented COVID-19-associated lung changes in computed tomography scans (53%). Common clinical manifestations included dyspnea, fever, and fatigue. Antiviral agents, like remdesivir, were employed in the remaining 4 cases (27%), and adjunctive therapies, such as corticosteroids and anticoagulants, were used selectively. All treated patients survived the infection without complications; the treatment proved effective and safe.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pneumonology and Allergology, Medical University of Gdansk, Poland. Electronic address: slawomir.zeglen@gumed.edu.pl.
- Temporary Hospital - Szczytno, Department of Internal Diseases and Infectious Diseases, Szczytno, Poland.
- Depatment of Cardiac Surgery, Medical University of Gdańsk, Poland.
- Scientific Circle of Lung Transplantology, Department of Lung Transplantation, Medical University of Gdansk, Poland.
- Emergency Department of Surgery (KAVA), Kristianstad, Sweden.
- Department of Applied Computer Science, AGH University of Science and Technology in Krakow, Poland.
Zitieren
APA
Żegleń, S., Nagajewski, A., Górski, D., Wojarski, J., Karlsen, W., Akily, L., Sunesson, F., Sawczuk, M., Nojek, R., Lipka, K., Gallas, M., Dukat-Mazurek, A., & Karolak, W. (2024). Treatment of Patients After Lung Transplantation With Covid Infection During Long-Term Follow-Up. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2024.03.010
Vancouver
Żegleń S, Nagajewski A, Górski D, Wojarski J, Karlsen W, Akily L, et al. Treatment of Patients After Lung Transplantation With Covid Infection During Long-Term Follow-Up. Transplantation Proceedings. 2024. doi:10.1016/j.transproceed.2024.03.010
BibTeX
@article{egle2024,
author = {Żegleń, Sławomir and Nagajewski, Adam and Górski, Dominik and Wojarski, Jacek and Karlsen, William and Akily, Lin and Sunesson, Fanny and Sawczuk, Marcin and Nojek, Rafał and Lipka, Karolina and Gallas, Marta and Dukat-Mazurek, Anna and Karolak, Wojtek},
title = {Treatment of Patients After Lung Transplantation With Covid Infection During Long-Term Follow-Up},
journal = {Transplantation Proceedings},
year = {2024},
doi = {10.1016/j.transproceed.2024.03.010}
}
EUVIMED